drugset / Trial / NCT07532486
A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis
Non-randomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability and drug survival of guselkumab in high-dose and extended-interval versus standard-dose in Chinese participants with moderate to severe plaque psoriasis.
Timeline
- Start
- 2024-07-10
- Primary completion
- 2027-07-10
- Completion
- 2027-07-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Guselkumab | Monoclonal antibody | 100 mg | Subcutaneous |
| Comparator | Guselkumab | Monoclonal antibody | 200 mg | Subcutaneous |